Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antiviral drug ganciclovir explored as new weapon against stubborn allergies

NCT ID NCT06436534

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial investigates whether the antiviral drug ganciclovir can help people with moderate-to-severe allergic rhinitis that doesn't improve with standard treatments. Participants receive either ganciclovir capsules or a placebo for two weeks, alongside a nasal steroid spray. Researchers track symptom scores and safety to see if ganciclovir offers additional relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ganciclovir
What this could lead to
If it works, this could offer a new treatment option for people with stubborn allergic rhinitis that doesn't respond well to standard care.
What could go wrong
This is a small, early-stage trial with only 50 participants. The drug may not prove effective or could have side effects. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHINITIS, ALLERGIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic rhinitis Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHINITIS, ALLERGIC

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Wuhan Union Hospital

    RECRUITING

    Wuhan, Hubei, 430022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.